immatics biotechnologies GmbH (4A3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, immatics biotechnologies GmbH (4A3) has a cash flow conversion efficiency ratio of -0.121x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-58.66 Million ≈ $-68.59 Million USD) by net assets (€484.10 Million ≈ $565.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 4A3 equity financing ratio to measure how much of total assets are equity-financed.
immatics biotechnologies GmbH - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how immatics biotechnologies GmbH's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 4A3 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
immatics biotechnologies GmbH Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of immatics biotechnologies GmbH ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Heritage Financial Corporation
NASDAQ:HFWA
|
0.013x |
|
Shenzhen hongfuhan Technology Co. Ltd.
SHE:301086
|
N/A |
|
Taiwan Hon Chuan Enterprise Co Ltd
TW:9939
|
0.099x |
|
GKG Precision Machine Co. Ltd. A
SHE:301338
|
-0.015x |
|
Naruida Technology Co. Ltd. Cl A
SHG:688522
|
N/A |
|
Lelon Electronics Corp
TW:2472
|
0.021x |
|
FuelCell Energy Inc
NASDAQ:FCEL
|
-0.037x |
|
Direcional Engenharia S.A.
SA:DIRR3
|
0.055x |
Annual Cash Flow Conversion Efficiency for immatics biotechnologies GmbH (2019–2025)
The table below shows the annual cash flow conversion efficiency of immatics biotechnologies GmbH from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see how much is immatics biotechnologies GmbH worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €484.10 Million ≈ $565.96 Million |
€-176.63 Million ≈ $-206.49 Million |
-0.365x | -32.72% |
| 2024-12-31 | €574.84 Million ≈ $672.05 Million |
€-158.03 Million ≈ $-184.75 Million |
-0.275x | -439.47% |
| 2023-12-31 | €225.08 Million ≈ $263.15 Million |
€18.23 Million ≈ $21.31 Million |
0.081x | -82.76% |
| 2022-12-31 | €213.16 Million ≈ $249.21 Million |
€100.13 Million ≈ $117.06 Million |
0.470x | -88.71% |
| 2021-12-31 | €24.06 Million ≈ $28.13 Million |
€100.13 Million ≈ $117.06 Million |
4.161x | +333.26% |
| 2020-12-31 | €104.26 Million ≈ $121.89 Million |
€100.13 Million ≈ $117.06 Million |
0.960x | +155.26% |
| 2019-12-31 | €-40.84 Million ≈ $-47.74 Million |
€70.97 Million ≈ $82.97 Million |
-1.738x | -- |
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecific… Read more